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  Abstract 
  




Melanoma is an aggressive cancer, which when diagnosed in the late stages has a median 
survival rate of 6 months. The current gold-standard for adjuvant therapy is high doses of the 
type I interferon (IFN)- 2, which prolongs disease free survival, but not overall survival. This 
high-dose therapy has many serious side-effects, resulting in doses to be lowered to sub-
therapeutic levels. It is not clear how IFN- 2 acts to treat melanoma, however it is accepted 
that immune enhancement is involved. The two main type I IFN families, IFN-  and IFN- , 
signal via the same receptor, however they have been found to be functionally different. Of 
the IFN-  family, 13 subtypes have been discovered and there is evidence that each is 
functionally unique. This project explores the therapeutic efficacy of seven type I IFN 
subtypes, including IFN- 2 and IFN- , in treating melanoma. To test efficacy, a model of 
DNA therapy to administer plasmids encoding the IFN subtypes was combined with a 
melanoma model utilizing B16 F1 cells expressing the immunogenic peptide glycoprotein B. 
We have found that the IFN-  subtypes tested have greater efficacy than IFN- 2 in treating 
melanoma. The IFN subtypes delayed tumour onset, and one subtype demonstrated a 
significant increase in survival time. In addition, therapeutic effects could be seen when sera 
levels were lower than that of IFN- 2. The in vitro effects of the IFN subtypes on melanoma 
cells was examined, uncovering differences in potency. Furthermore, we have found evidence 
of anti-tumour immune enhancement is associated with IFN-  therapy but not IFN- . This 
research shows that the IFN-  subtypes differ in their anti-tumour efficacy, and potency of 
actions. Therefore the IFN-  subtypes show potential as a superior therapy in treating 
melanoma, which may be administered at lower, less toxic doses. 
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